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shown that Adacolumn changed the cellular immunity and pro-
moted an early virological response.
http://dx.doi.org/10.1016/j.ijid.2012.05.23015th ICID Abstracts / International Journ
s high as 58.2% in multi-transfused children, 51.6% in children on
emodialysis and 87.5% in adult dialysis patients. Among popula-
ions at indirect risk, family contacts of HCV positive individuals
ad a prevalence of 5.7%, diabetic children a prevalence of 3.1%,
elect professions such as barbers 12.3%, and health care workers
5.7%, while Injection drug users and prisoners had a prevalence
f 63% and 31.4%, respectively. Common risk factors appear to
e increasing age, parenteral anti-schistosomal therapy, frequent
ransfusions, injections or surgical procedures.
Conclusion: With the highest HCV prevalence in the world,
gypt appears to be experiencing an HCV epidemic. High HCV
revalence levels especially among select clinical populations, is
ndicative of ongoing iatrogenic transmission. Therefore, preven-
ion programs need to be developed targeting HCV transmission
outes suchasbetter infection control practices inhospitals, health-
are and dental care facilities.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.228
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ersistance of HBsAg, liver enzyme changes and risk factors of
epatitis B infection among chronic carriers of hepatitis B
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kashan university of medical sciences, kashan, isfahan, Iran, Islamic
epublic of
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infectios disease department, kashan, Iran, Islamic Republic of
Background: Hepatitis B virus (HBV) infection and its sequelae
re major global health problems. It is estimated that 400 million
eople worldwide are HBV carriers.This study was conducted to
valuateHBsAgpersistence, risk factors ofHBV infection anddetect
f HBeAg positive cases and abnormal liver enzyme tests among
hronic HBV carriers in Kashan
Methods: This descriptive study was performed in HBsAg pos-
tive blood donors who detected after blood donation during 10
ears ago. They were invited to retest HBsAg. After obtaining con-
ent form a questionnaire consisting demographic and history of
isk factors of HBV infection were ﬁlled by interviewing and then
cc blood was taken from cases and HBsAg was measured by ELISA
ethod. Who had HBsAg positive test HBeAg, liver enzyme tests
eremeasured .The results were analyzed by SPSS,ﬁsher exact and
test.
Results: Of 150 HBsAg positive blood donors 124(83.7%) were
ale and26(17.3%) female. Persistence and clearance ofHBsAgwas
een in 132(88%) and18(12%)respectovely .There was no signiﬁ-
ant statistical correlation between sex, age,marital status, history
f icther,endoscpy,tattoo.transfusion,with persistence of HBsAg .(P
alue>0.05)
HBeAg was positive in 18.2% of HBsAg positive cases. There was
bnormal aminotransferase There was no statistical correlation
etween ALT, AST and ALKP with HBeAg (P value>0.05) .Chronic
epatitis B was detected in three patient.
Conclusion: Considering the lower rate of clearance of
BsAg,and also detecting of suspected cases of chronic hepati-
is,determine of HBeAg state and periodic examination of livernfectious Diseases 16S (2012) e2–e157 e99
enzyme test seems to be essential in follow up in chronic HBV
carriers.
http://dx.doi.org/10.1016/j.ijid.2012.05.229
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Leukocytapheresis treatment for recurrenceVirus C infection in
liver transplant recipients
V. Morabito ∗, G. Ferretti, M. Rossi, G. Novelli
Sapienza University, Rome, Italy
Background: In liver transplant (LT) recipients, persistence of
hepatitis C (HCV) infection in viremic recipients almost always
leads to graft reinfection. Although HCV is a hepatocellular
pathogen, there is increasing evidence that the virus can infect
and persist in other cells. In particular, granulocytes and mono-
cytes/macrophages are known to constitute extra-hepatic sites for
HCV replication and dissemination. The aim of this study was to
apply Adacolumn apheresis as a possible therapeutic alternative to
conventional drug therapy in the management of HCV infection.
Methods: Seven patients who received liver transplantation for
Virus C-related cirrhosis were eligible for the study. The patients
underwent ﬁve 1-hour sessions for 5 consecutive days. First treat-
ment was performed in the anhepatic phase of liver transplant
with the intent to early reduce infected granulocytes and mono-
cytes/macrophages. The patients were evaluated during the 5 days
after inclusion with and 6-month follow-up.
Results: Early apheretic treatment in anhepatic phase and for
the following 4 days after transplant determined low viral load in
four LT patients, negative viral load in two patients and an increase
in viremia values in one patient. At follow up the viremia load was
stable in 7 patients without an increase of transaminases levels. At
the end of treatment cycle almost all immune cells of six patients
showed maintained CD4+/CD8+ T cells ratio.
Conclusion: The optimal timing of treatment initiation is
unknown, but an early preemptive therapy is recommended to
decrease the risks for recurrence of infection. Although this study
investigated the responses in a small number of patients, it was
